Supplemental financial information (Tables)

6 Months Ended

Jun. 30, 2018

Supplemental financial information

Schedule of cash, cash equivalents and restricted cash

The following table provides a reconciliation of cash, cash equivalents, and restricted cash reported within the balance sheets that sum to the total of the same such amounts shown in the statements of cash flows (amounts in thousands).

	As of		As of
	June 30,		December 31,
	2018		2017
Cash and cash equivalents	$	179,090	$	92,136
Restricted cash		473		473
Total cash, cash equivalents, and restricted cash shown in the statements of cash flows	$	179,563	$	92,609

Schedule of prepaid expenses and other current assets

Prepaid expenses and other current assets consist of the following (in thousands):

	As of		As of
	June 30,		December 31,
	2018		2017
Prepaid clinical	$	7	$	1,718
Other current assets		364		242
Total prepaid expenses and other current assets	$	371	$	1,960

Schedule of accrued expenses and other current liabilities

Accrued expenses and other current liabilities consist of the following (in thousands):

	As of		As of
	June 30,		December 31,
	2018		2017
Employee-related expenses	$	1,107	$	1,435
Development costs and sponsored research		1,732		737
Clinical trials		1,503		69
Deferred rent		293		309
Deferred offering costs		1,086		—
Other		176		285
Total accrued expenses and other current liabilities	$	5,897	$	2,835